ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.131
AS - Asia 17.464
EU - Europa 9.499
SA - Sud America 2.466
Continente sconosciuto - Info sul continente non disponibili 540
AF - Africa 423
OC - Oceania 50
Totale 64.573
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.347
SG - Singapore 5.132
CN - Cina 3.432
HK - Hong Kong 3.045
VN - Vietnam 2.036
IT - Italia 1.922
BR - Brasile 1.846
GB - Regno Unito 1.845
BD - Bangladesh 1.216
FI - Finlandia 1.136
SE - Svezia 1.062
KR - Corea 720
RU - Federazione Russa 708
DE - Germania 626
FR - Francia 385
CA - Canada 384
BG - Bulgaria 372
IN - India 369
PL - Polonia 360
AR - Argentina 245
TR - Turchia 237
ID - Indonesia 236
NL - Olanda 177
UA - Ucraina 175
JP - Giappone 167
MX - Messico 160
ZA - Sudafrica 149
IQ - Iraq 146
AE - Emirati Arabi Uniti 127
ES - Italia 124
AT - Austria 108
CO - Colombia 89
EC - Ecuador 77
LT - Lituania 77
PK - Pakistan 76
IE - Irlanda 74
EG - Egitto 60
CL - Cile 59
MA - Marocco 54
SA - Arabia Saudita 54
CR - Costa Rica 53
CZ - Repubblica Ceca 51
UZ - Uzbekistan 51
PH - Filippine 48
VE - Venezuela 48
MY - Malesia 44
BE - Belgio 40
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 36
JM - Giamaica 35
AU - Australia 34
TN - Tunisia 31
KZ - Kazakistan 28
IL - Israele 27
NP - Nepal 27
HN - Honduras 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
TH - Thailandia 23
AL - Albania 22
CH - Svizzera 21
ET - Etiopia 21
UY - Uruguay 20
IR - Iran 19
BO - Bolivia 18
GR - Grecia 18
NO - Norvegia 17
PT - Portogallo 17
DO - Repubblica Dominicana 16
GT - Guatemala 16
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
BH - Bahrain 14
DK - Danimarca 14
TT - Trinidad e Tobago 14
TW - Taiwan 14
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
LB - Libano 12
MK - Macedonia 12
NI - Nicaragua 12
GE - Georgia 11
MD - Moldavia 11
PR - Porto Rico 11
SV - El Salvador 11
HU - Ungheria 10
LV - Lettonia 10
QA - Qatar 10
EE - Estonia 9
KH - Cambogia 9
BY - Bielorussia 8
BZ - Belize 8
SK - Slovacchia (Repubblica Slovacca) 8
CY - Cipro 7
HR - Croazia 7
BA - Bosnia-Erzegovina 6
Totale 63.899
Salva come PNG Salva come JPEG
Città #
Ashburn 3.767
Santa Clara 3.691
Singapore 3.284
Hong Kong 2.983
Fairfield 2.374
Chandler 2.080
San Jose 1.115
Helsinki 1.087
New York 1.044
London 995
Nyköping 857
Woodbridge 849
Council Bluffs 845
Houston 825
Wilmington 757
Los Angeles 734
Hefei 706
Seattle 705
Ho Chi Minh City 644
Cambridge 626
Beijing 617
Seoul 590
The Dalles 567
Chicago 512
Hanoi 506
Ann Arbor 477
San Diego 474
Boardman 398
Princeton 372
Sofia 359
Southend 344
Warsaw 338
Milan 293
Sunnyvale 284
Buffalo 279
North Bergen 229
Piscataway 223
Moscow 221
Orem 218
Shanghai 197
Salt Lake City 195
Modena 185
Jersey City 182
Dallas 178
São Paulo 174
Jacksonville 161
Secaucus 161
Jakarta 156
Dearborn 152
Phoenix 125
Tokyo 123
Atlanta 116
Rome 116
Redondo Beach 115
Da Nang 110
Istanbul 106
Newark 103
Clifton 99
Porto Alegre 97
Frankfurt am Main 93
Lauterbourg 90
Chennai 89
Toronto 89
Denver 87
Haiphong 87
Johannesburg 87
Bremen 86
Brooklyn 85
Bupyeong-gu 84
San Francisco 79
Tampa 77
Bologna 73
Montreal 69
Dublin 68
Vienna 68
Elk Grove Village 66
Munich 66
Amsterdam 60
Mexico City 60
Naples 58
Charlotte 57
Norwalk 57
Rio de Janeiro 56
Columbus 54
Stockholm 53
Augusta 52
Boston 52
Manchester 52
Miami 52
Miano 52
Nuremberg 52
Philadelphia 51
Viroflay 51
Guangzhou 49
Paris 49
Izmir 48
Des Moines 47
Reading 46
Baghdad 45
Biên Hòa 45
Totale 42.761
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 1.276
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis 563
Non-alcoholic steatohepatitis and liver transplantation 531
Side Effects of Immunosuppressant Drugs After Liver Transplant 458
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 392
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 391
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 372
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 370
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 352
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 351
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 345
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 330
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 329
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 326
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 326
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 323
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 312
From current status to optimization of HCV treatment: Recommendations from an expert panel 302
Missed treatment in an Italian HBV infected patients cohort: HBV RER 296
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 294
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 294
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 291
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool 287
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 283
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 283
Global multi-stakeholder endorsement of the MAFLD definition 269
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 268
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 266
Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension 266
Treatment of nonalcoholic steatohepatitis in adults: present and future 264
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 263
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 263
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 260
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 259
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 257
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 256
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 253
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B 252
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 249
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 247
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 244
Adaptive response in Hepatitis B virus infection 243
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 241
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 240
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 239
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 239
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 238
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 236
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 234
Characteristics of hepatocellular carcinoma in Italy 232
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 232
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 232
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 231
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 230
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 227
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 226
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 225
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 225
Alcohol and viral hepatitis: a mini-review 223
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 221
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 220
Update on Alcohol and Viral Hepatitis 216
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 215
CD 133+ stem cells for the treatment of end stage liver disease 214
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 214
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 214
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 213
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 212
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 211
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 210
Gross pathologic types of hepatocellular carcinoma in Italy. 209
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 209
Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C 209
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 209
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 207
Clinical and serological profile of primary biliary cirrhosis in men 207
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 205
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 204
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 204
Familial intrahepatic cholestasis: New and wide perspectives 203
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 203
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 202
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 201
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 201
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): A randomised, double-blind, non-inferiority phase 3 trial 201
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 201
Chronic hepatitis B: Are we close to a cure? 200
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 199
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 198
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 198
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 195
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 194
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 194
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 193
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 193
Virological Treatment Monitoring for Chronic Hepatitis B 192
Characterization of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver 191
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 190
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 190
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 189
Totale 26.357
Salva come PNG Salva come JPEG
Categoria #
all - tutte 321.301
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 321.301
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.404 0 0 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202627.515 1.254 771 1.937 2.630 3.300 2.823 3.041 1.658 2.592 2.540 2.539 2.430
2026/20274.452 1.871 2.414 167 0 0 0 0 0 0 0 0 0
Totale 64.573